Private equity firm Warburg Pincus LLC said on Tuesday it had agreed to invest up to $300 million in Vertice Pharma, a British pharmaceuticals company that will focus on buying drug makers and their products. Vertice Pharma will be a partnership between Warburg Pincus and two pharmaceutical executives, the private equity firm said in a statement. Among its first acquisitions, Vertice has struck a deal to buy VistaPharm, a specialized manufacturer of pain medication, Warburg Pincus said, without disclosing the details of the transaction. Based in New York, Warburg Pincus manages over $35 billion worth of assets.
Source: Reuters.comWarburg Pincus to invest up to $300 mln in Vertice Pharma
Industry: Pharmaceutical 2015-11-18